St Jude CE marks Penta neurostimulation lead; also approved in Australia
This article was originally published in Clinica
St Jude Medical has CE marked its Penta surgical lead for neurostimulation therapy. The company has also obtained regulatory and reimbursement approval from the Australian Therapeutic Goods Administration (TGA) for the device. The lead is designed to treat chronic pain of the trunk and limbs and pain from back surgeries that have failed. It delivers mild electrical pulses to interrupt or mask the transmission of pain signals to the brain. Electrodes on the lead can be programmed to meet individual patients' needs. The St Paul, Minnesota-based company claims that the five-column surgical lead is the first of its kind, and features the smallest electrodes on the market. The Penta lead gained US premarket approval (PMA) last year (www.clinica.co.uk, 7 December 2009).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.